Cargando…

Hyperprogressive Disease In a Metastatic Renal Cell Carcinoma Patient After Receiving Immune Checkpoint Inhibitors: A Case Report

Owing to their survival benefits, immune checkpoint inhibitors (ICIs) have emerged as the mainstay treatment for several types of malignant tumors including renal cell carcinoma (RCC). However, the usage of ICIs such as nivolumab, ipilimumab, and atezolizumab can be complicated by unexpected rapid c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alkader, Mohammad, Altaha, Rashed, Alkhatib, Lean, Jabali, Eslam H, Alsoreeky, Mohammad S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Internal Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9651922/ https://www.ncbi.nlm.nih.gov/pubmed/36381823 http://dx.doi.org/10.7759/cureus.30194

Ejemplares similares

Impact of KRAS Mutation on Survival Outcome of Patients With Metastatic Colorectal Cancer in Jordan
por: Alkader, Mohammad S, et al.
Publicado: (2023)

The Impact of Palliative Chemotherapy on the Survival of Patients With Metastatic Colorectal Cancer in Jordan
por: Alkader, Mohammad S, et al.
Publicado: (2023)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Hyperprogressive NSCLC With Two Immune-Checkpoint Inhibitors
por: Kasparian, Saro, et al.
Publicado: (2020)

Hyperprogression of Liver Metastasis With Neoadjuvant Immunotherapy for Soft Tissue Sarcoma
por: Chan, Abigail S, et al.
Publicado: (2020)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
por: Shen, Pan, et al.
Publicado: (2021)

Hyperprogression: A Unique Phenomenon of Progression of Existing Tumor Secondary to Immunotherapy
por: Mandal, Shobha, et al.
Publicado: (2021)

Hyperprogression in Pediatric Melanoma Metastatic to the Breast Treated with a Checkpoint Inhibitor
por: Bernal Vaca, Laura, et al.
Publicado: (2019)

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
por: Zang, Hongjing, et al.
Publicado: (2020)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting
por: Kanjanapan, Yada, et al.
Publicado: (2023)

Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis
por: Verma, Neha, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-Induced Lymphocytic Esophagitis
por: Amin, Shefali, et al.
Publicado: (2023)

Isolated Neutropenia Due to Immune Checkpoint Inhibitors
por: Jalil, Ahmad, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Associated Thrombotic Thrombocytopenic Purpura in a Patient With Metastatic Non-Small-Cell Lung Cancer
por: De Filippis, Samantha, et al.
Publicado: (2021)

How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
por: Denis, Morgane, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Induced Acute Pancreatitis and Colitis
por: Pagan, Andrea, et al.
Publicado: (2020)

Influence of Microbiome and Antibiotics on the Efficacy of Immune Checkpoint Inhibitors
por: Patel, Priyanka, et al.
Publicado: (2021)

Role of Immune Checkpoint Inhibitors in Advanced or Recurrent Endometrial Cancer
por: Arora, Ena, et al.
Publicado: (2018)

Immune Checkpoint Inhibitor-Induced Colitis Presenting As Lymphocytic Colitis
por: Khan, Jaffar, et al.
Publicado: (2021)

Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
por: Soria, Francesco, et al.
Publicado: (2018)

Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
por: Refae, Sadal, et al.
Publicado: (2020)

Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor
por: Xu, Zihan, et al.
Publicado: (2019)

Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review
por: Liu, Xiaojun, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies
por: Maung, Tun Zan, et al.
Publicado: (2020)

Prediction model for hyperprogressive disease in patients with advanced solid tumors received immune-checkpoint inhibitors: a pan-cancer study
por: Long, Yaping, et al.
Publicado: (2023)

Redefine Hyperprogressive Disease During Treatment With Immune-Checkpoint Inhibitors in Patients With Gastrointestinal Cancer
por: Wang, Zhenghang, et al.
Publicado: (2021)

Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
por: Wei, Zhanqi, et al.
Publicado: (2022)

Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don’t) know
por: Camelliti, Simone, et al.
Publicado: (2020)

Author Correction: Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
por: Refae, Sadal, et al.
Publicado: (2020)

A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer
por: Cao, Shuhui, et al.
Publicado: (2022)

Seronegative Rheumatoid Arthritis Secondary to Immune Checkpoint Inhibitor in a Renal Cell Carcinoma Patient Encountered in a Rural Community-Based Rheumatology Clinic: A Case Report
por: De Camps Martinez, Elmer R, et al.
Publicado: (2023)

Multiple White Plaques in the Esophagus: A Possible Case of Esophageal Mucosal Alteration Associated With Immune-Related Adverse Events of Immune Checkpoint Inhibitors
por: Iwamuro, Masaya, et al.
Publicado: (2022)

Prediction model for hyperprogressive disease in non‐small cell lung cancer treated with immune checkpoint inhibitors
por: Choi, Yong Jun, et al.
Publicado: (2020)

Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma
por: Schuiveling, M., et al.
Publicado: (2020)

Metastatic Renal Cell Cancer With Pancreatic Mass
por: Chaudhary, Sushant, et al.
Publicado: (2022)

The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy
por: Sabio, Erich, et al.
Publicado: (2019)

Weight Changes in Women Receiving Chemotherapy for Non-Metastatic Breast Cancer in Saudi Arabia
por: Al-Hajeili, Marwan, et al.
Publicado: (2021)

A Novel Workflow to Create a Checkpoint Inhibitor Pneumonitis Patient Registry
por: Faucheux, Andrew, et al.
Publicado: (2023)

Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?
por: Britt, Alec S., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tj5te3e62gqnsrdtd8ganffgo2